|
|
Advances in COVID-19: the virus, the pathogenesis, and evidence-based control and therapeutic strategies |
Guangbiao Zhou1(), Saijuan Chen2, Zhu Chen2() |
1. State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China 2. State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine (Shanghai), Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China |
|
|
Abstract Since the outbreak of the COVID-19 pandemic in early December 2019, 81 174 confirmed cases and 3242 deaths have been reported in China as of March 19, 2020. The Chinese people and government have contributed huge efforts to combat this disease, resulting in significant improvement of the situation, with 58 new cases (34 were imported cases) and 11 new deaths reported on March 19, 2020. However, as of March 19, 2020, the COVID-19 pandemic continues to develop in 167 countries/territories outside of China, and 128 665 confirmed cases and 5536 deaths have been reported, with 16 498 new cases and 817 new deaths occurring in last 24 hours. Therefore, the world should work together to fight against this pandemic. Here, we review the recent advances in COVID-19, including the insights in the virus, the responses of the host cells, the cytokine release syndrome, and the therapeutic approaches to inhibit the virus and alleviate the cytokine storm. By sharing knowledge and deepening our understanding of the virus and the disease pathogenesis, we believe that the community can efficiently develop effective vaccines and drugs, and the mankind will eventually win this battle against this pandemic.
|
Keywords
COVID-19
SARS-CoV-2
pathogenesis
evidence-based medicine
control and therapeutic strategies
|
Corresponding Author(s):
Guangbiao Zhou,Zhu Chen
|
Just Accepted Date: 21 March 2020
Online First Date: 20 April 2020
Issue Date: 09 May 2020
|
|
1 |
R Yan, Y Zhang, Y Li, L Xia, Y Guo, Q Zhou. Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. Science 2020 Mar 4. [Epub ahead of print] doi: 10.1126/science.abb2762
https://doi.org/10.1126/science.abb2762
|
2 |
World Health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). 2020.
|
3 |
World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report — 59. March 19, 2020.
|
4 |
World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report — 37. February 26, 2020.
|
5 |
Y Zhang, D Cao. Wuhan to close its largest makeshift hospital. China Daily. March 7, 2020.
|
6 |
World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19 — 11 March 2020. March 11, 2020.
|
7 |
S Kannan, P Shaik Syed Ali, A Sheeza, K Hemalatha. COVID-19 (novel coronavirus 2019) — recent trends. Eur Rev Med Pharmacol Sci 2020; 24(4): 2006–2011
https://doi.org/10.26355/eurrev_202002_20378
pmid: 32141569
|
8 |
M Wang, R Cao, L Zhang, X Yang, J Liu, M Xu, Z Shi, Z Hu, W Zhong, G Xiao. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30(3): 269–271
https://doi.org/10.1038/s41422-020-0282-0
pmid: 32020029
|
9 |
X Tang, C Wu, X Li, Y Song, X Yao, X Wu, Y Duan, H Zhang, Y Wang, Z Qian, J Cui, J Lu. On the origin and continuing evolution of SARS-CoV-2. Natl Sci Rev 2020 Mar 3. [Epub ahead of print] doi:10.1093/nsr/nwaa036
https://doi.org/10.1093/nsr/nwaa036
|
10 |
OA Maclean, R Orton, J Singer, DL Robertson. Response to “On the origin and continuing evolution of SARS-CoV-2”. 2020.
|
11 |
L Zhang, J-R Yang, Z Zhang, Z Lin. Genomic variations of SARS-CoV-2 suggest multiple outbreak sources of transmission. medRxiv 2020; doi: 10.1101/2020.02.25.20027953
https://doi.org/10.1101/2020.02.25.20027953
|
12 |
C Ceraolo, FM Giorgi. Genomic variance of the 2019-nCoV coronavirus. J Med Virol 2020; 92: 522–528
https://doi.org/10.1002/jmv.25700
|
13 |
A Wu, P Niu, L Wang, H Zhou, X Zhao, W Wang, et al.. Mutations, recombination and insertion in the evolution of 2019-nCoV. bioRxiv 2020; doi: 10.1101/2020.02.29.971101
https://doi.org/10.1101/2020.02.29.971101
|
14 |
WB Yu, GD Tang, L Zhang, RT Corlett. Decoding evolution and transmissions of novel pneumonia coronavirus using the whole genomic data. ChinaXiv 2020.
|
15 |
KG Andersen, A Rambaut, WI Lipkin, EC Holmes, RF Garry. The proximal origin of SARS-CoV-2. Nat Med 2020. [Epub ahead of print] doi: 10.1038/s41591-020-0820-9
https://doi.org/10.1038/s41591-020-0820-9
|
16 |
H Liu, C Wu, Y Yang, Y Liu, P Zhang, Y Wang, Q Wang, et al.. Furin, a potential therapeutic target for COVID-19. ChinaXiv 2020.
|
17 |
M Hoffmann, H Kleine-Weber, S Schroeder, N Krüger, T Herrler, S Erichsen, TS Schiergens, G Herrler, NH Wu, A Nitsche, MA Müller, C Drosten, S Pöhlmann. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020 Mar 4. [Epub ahead of print] doi: 10.1016/j.cell.2020.02.052
https://doi.org/10.1016/j.cell.2020.02.052
pmid: 32142651
|
18 |
X Zou, K Chen, J Zou, P Han, J Hao, Z Han. The single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med 2020 Mar 12. [Epub ahead of print] doi: 10.1007/s11684-020-0754-0
https://doi.org/10.1007/s11684-020-0754-0
|
19 |
L Du, Y He, Y Zhou, S Liu, BJ Zheng, S Jiang. The spike protein of SARS-CoV—a target for vaccine and therapeutic development. Nat Rev Microbiol 2009; 7(3): 226–236
https://doi.org/10.1038/nrmicro2090
pmid: 19198616
|
20 |
R Lu, X Zhao, J Li, P Niu, B Yang, H Wu, W Wang, H Song, B Huang, N Zhu, Y Bi, X Ma, F Zhan, L Wang, T Hu, H Zhou, Z Hu, W Zhou, L Zhao, J Chen, Y Meng, J Wang, Y Lin, J Yuan, Z Xie, J Ma, WJ Liu, D Wang, W Xu, EC Holmes, GF Gao, G Wu, W Chen, W Shi, W Tan. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020; 395(10224): 565–574
https://doi.org/10.1016/S0140-6736(20)30251-8
pmid: 32007145
|
21 |
N Chen, M Zhou, X Dong, J Qu, F Gong, Y Han, Y Qiu, J Wang, Y Liu, Y Wei, J Xia, T Yu, X Zhang, L Zhang. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223): 507–513
https://doi.org/10.1016/S0140-6736(20)30211-7
pmid: 32007143
|
22 |
D Wang, B Hu, C Hu, F Zhu, X Liu, J Zhang, B Wang, H Xiang, Z Cheng, Y Xiong, Y Zhao, Y Li, X Wang, Z Peng. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323(11): 1061
https://doi.org/10.1001/jama.2020.1585
pmid: 32031570
|
23 |
WJ Guan, ZY Ni, Y Hu, WH Liang, CQ Ou, JX He, L Liu, H Shan, CL Lei, DSC Hui, B Du, LJ Li, G Zeng, KY Yuen, RC Chen, CL Tang, T Wang, PY Chen, J Xiang, SY Li, JL Wang, ZJ Liang, YX Peng, L Wei, Y Liu, YH Hu, P Peng, JM Wang, JY Liu, Z Chen, G Li, ZJ Zheng, SQ Qiu, J Luo, CJ Ye, SY Zhu, NS Zhong; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020 Feb 28. [Epub ahead of print] doi: 10.1056/NEJMoa2002032
https://doi.org/10.1056/NEJMoa2002032
pmid: 32109013
|
24 |
J Liu, S Li, J Liu, B Liang, X Wang, H Wang, et al.. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. medRxiv 2020; doi: 10.1101/2020.02.16.20023671
https://doi.org/10.1101/2020.02.16.20023671
|
25 |
B Diao, C Wang, Y Tan, X Chen, Y Liu, L Ning, et al.. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). medRxiv 2020; doi: 10.1101/2020.02.18.20024364
https://doi.org/10.1101/2020.02.18.20024364
|
26 |
Z Zhang, X Li, W Zhang, ZL Shi, Z Zheng, T Wang. Clinical features and treatment of 2019-nCov pneumonia patients in Wuhan: report of a couple cases. Virol Sin 2020 Feb 7. [Epub ahead of print] doi: 10.1007/s12250-020-00203-8
https://doi.org/10.1007/s12250-020-00203-8
pmid: 32034637
|
27 |
W Wang, J He, P Lie, L Huang, S Wu, Y Lin, et al.. The definition and risks of cytokine release syndrome-like in 11 COVID-19-infected pneumonia critically ill patients: disease characteristics and retrospective analysis. medRxiv 2020; doi: 10.1101/2020.02.26. 20026989
https://doi.org/10.1101/2020.02.26.20026989
|
28 |
A Nazinitsky, KS Rosenthal. Cytokine storms: systemic disasters of infectious diseases. Infect Dis Clin Pract 2010; 18(3): 188–192
https://doi.org/10.1097/IPC.0b013e3181d2ee41
|
29 |
L Chatenoud, C Ferran, A Reuter, C Legendre, Y Gevaert, H Kreis, P Franchimont, JF Bach. Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-γ [corrected]. N Engl J Med 1989; 320(21): 1420–1421
https://doi.org/10.1056/NEJM198905253202117
pmid: 2785642
|
30 |
EM Behrens. Cytokines in cytokine storm syndrome. In: Cron RQ, Behrens EM. Cytokine Storm Syndrome. Cham: Springer International Publishing, 2019. 197–207
|
31 |
T Okabayashi, H Kariwa, S Yokota, S Iki, T Indoh, N Yokosawa, I Takashima, H Tsutsumi, N Fujii. Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections. J Med Virol 2006; 78(4): 417–424
https://doi.org/10.1002/jmv.20556
pmid: 16482545
|
32 |
JR Teijaro, KB Walsh, S Cahalan, DM Fremgen, E Roberts, F Scott, E Martinborough, R Peach, MB Oldstone, H Rosen. Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell 2011; 146(6): 980–991
https://doi.org/10.1016/j.cell.2011.08.015
pmid: 21925319
|
33 |
R Channappanavar, S Perlman. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol 2017; 39(5): 529–539
https://doi.org/10.1007/s00281-017-0629-x
pmid: 28466096
|
34 |
T Liu, J Zhang, Y Yang, H Ma, Z Li, J Zhang, et al.. The potential role of IL-6 in monitoring severe case of coronavirus disease 2019. medRxiv 2020; doi: 10.1101/2020.03.01.20029769
https://doi.org/10.1101/2020.03.01.20029769
|
35 |
L Yu, Y Tong, G Shen, A Fu, Y Lai, X Zhou, et al.. Immunodepletion with hypoxemia: a potential high risk subtype of coronavirus disease 2019. medRxiv 2020; doi: 10.1101/2020. 03.03.20030650
https://doi.org/10.1101/2020.03.03.20030650
|
36 |
Z Xu, L Shi, Y Wang, J Zhang, L Huang, C Zhang, S Liu, P Zhao, H Liu, L Zhu, Y Tai, C Bai, T Gao, J Song, P Xia, J Dong, J Zhao, FS Wang. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020 Feb 18. [Epub ahead of print] doi: 10.1016/S2213-2600(20)30076-X
https://doi.org/10.1016/S2213-2600(20)30076-X
pmid: 32085846
|
37 |
Y Zhou, B Fu, X Zheng, D Wang, C Zhao, Y Qi, et al.. Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus. bioRxiv 2020; doi: 10.1101/2020.02.12.945576
https://doi.org/10.1101/2020.02.12.945576
|
38 |
KJ Huang, IJ Su, M Theron, YC Wu, SK Lai, CC Liu, HY Lei. An interferon-g-related cytokine storm in SARS patients. J Med Virol 2005; 75(2): 185–194
https://doi.org/10.1002/jmv.20255
pmid: 15602737
|
39 |
W Luo, H Yu, J Gou, X Li, Y Sun, J Li, L Liu. Clinical pathology of critical patient with novel coronavirus pneumonia (COVID-19). Preprints 2020; 2020020407
|
40 |
P Zhou, XL Yang, XG Wang, B Hu, L Zhang, W Zhang, HR Si, Y Zhu, B Li, CL Huang, HD Chen, J Chen, Y Luo, H Guo, RD Jiang, MQ Liu, Y Chen, XR Shen, X Wang, XS Zheng, K Zhao, QJ Chen, F Deng, LL Liu, B Yan, FX Zhan, YY Wang, GF Xiao, ZL Shi. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579(7798): 270–273
https://doi.org/10.1038/s41586-020-2012-7
pmid: 32015507
|
41 |
C Anastassopoulou, L Russo, A Tsakris, C. Siettos Data-based analysis, modelling and forecasting of the novel coronavirus (2019-nCoV) outbreak. medRxiv 2020; doi: 10.1101/2020.02.11. 20022186
https://doi.org/10.1101/2020.02.11.20022186
|
42 |
Q Li, X Guan, P Wu, X Wang, L Zhou, Y Tong, R Ren, KSM Leung, EHY Lau, JY Wong, X Xing, N Xiang, Y Wu, C Li, Q Chen, D Li, T Liu, J Zhao, M Liu, W Tu, C Chen, L Jin, R Yang, Q Wang, S Zhou, R Wang, H Liu, Y Luo, Y Liu, G Shao, H Li, Z Tao, Y Yang, Z Deng, B Liu, Z Ma, Y Zhang, G Shi, TTY Lam, JTK Wu, GF Gao, BJ Cowling, B Yang, GM Leung, Z Feng. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020 Jan 29. [Epub ahead of print] doi: 10.1056/NEJMoa2001316
https://doi.org/10.1056/NEJMoa2001316
pmid: 31995857
|
43 |
Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Chin J Epidemiol (Zhonghua Liu Xing Bing Xue Za Zhi) 2020; 41(2): 145–151 (in Chinese)
pmid: 32064853
|
44 |
K Duan, B Liu, C Li, H Zhang, T Yu, J Qu, et al.. The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study. Proc Natl Acad Sci USA 2020; doi: 10.1073/pnas.2004168117
https://doi.org/10.1016/S1473-3099(20)30141-9
pmid: 32113510
|
45 |
L Chen, J Xiong, L Bao, Y Shi. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis 2020 Feb 27. [Epub ahead of print] doi: 10.1016/S1473-3099(20)30141-9
https://doi.org/10.1016/S1473-3099(20)30141-9
pmid: 32113510
|
46 |
ML Holshue, C DeBolt, S Lindquist, KH Lofy, J Wiesman, H Bruce, C Spitters, K Ericson, S Wilkerson, A Tural, G Diaz, A Cohn, L Fox, A Patel, SI Gerber, L Kim, S Tong, X Lu, S Lindstrom, MA Pallansch, WC Weldon, HM Biggs, TM Uyeki, SK Pillai; Washington State 2019-nCoV Case Investigation Team. First case of 2019 novel coronavirus in the United States. N Engl J Med 2020; 382(10): 929–936
https://doi.org/10.1056/NEJMoa2001191
pmid: 32004427
|
47 |
N Zhu, D Zhang, W Wang, X Li, B Yang, J Song, X Zhao, B Huang, W Shi, R Lu, P Niu, F Zhan, X Ma, D Wang, W Xu, G Wu, GF Gao, W Tan; China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382(8): 727–733
https://doi.org/10.1056/NEJMoa2001017
pmid: 31978945
|
48 |
V Staedtke, RY Bai, K Kim, M Darvas, ML Davila, GJ Riggins, PB Rothman, N Papadopoulos, KW Kinzler, B Vogelstein, S Zhou. Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. Nature 2018; 564(7735): 273–277
https://doi.org/10.1038/s41586-018-0774-y
pmid: 30542164
|
49 |
NR London, W Zhu, FA Bozza, MCP Smith, DM Greif, LK Sorensen, et al.. Targeting Robo4-dependent Slit signaling to survive the cytokine storm in sepsis and influenza. Sci Transl Med 2010; 2(23): 23ra19
https://doi.org/10.1126/scitranslmed.3000678
|
50 |
X Liu, Z Li, S Liu, Z Chen, Z Zhao, YY Huang, et al.. Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction. medRxiv 2020; doi: 10.1101/2020.02.27.20027557
https://doi.org/10.1101/2020.02.27.20027557
|
51 |
S Pfaender, KB Mar, E Michailidis, A Kratzel, D Hirt, P V’kovski, et al.. LY6E impairs coronavirus fusion and confers immune control of viral disease. bioRxiv 2020; doi: 10.1101/2020.03.05.979260
https://doi.org/10.1101/2020.03.05.979260
|
52 |
C Wu, Y Liu, Y Yang, P Zhang, W Zhong, Y Wang, Q Wang, Y Xu, M Li, X Li, M Zheng, L Chen, H Li. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B 2020 Feb 27. [Epub ahead of print] doi:10.1016/j.apsb.2020.02.008
https://doi.org/10.1016/j.apsb.2020.02.008
|
53 |
A Rimanshee, D Amit, P Vishal, K Mukesh. Potential inhibitors against papain-like protease of novel coronavirus (SARS-CoV-2) from FDA approved drugs. ChemRxiv 2020; doi: 10.26434/chemrxiv.11860011.v2
https://doi.org/10.26434/chemrxiv.11860011.v2
|
54 |
ul Tahir M Qamar, S Alqahtani, M Alamri, L Chen. Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants. Preprints 2020; 2020020193
|
55 |
B Cao, Y Wang, D Wen, W Liu, J Wang, G Fan, L Ruan, B Song, Y Cai, M Wei, X Li, J Xia, N Chen, J Xiang, T Yu, T Bai, X Xie, L Zhang, C Li, Y Yuan, H Chen, H Li, H Huang, S Tu, F Gong, Y Liu, Y Wei, C Dong, F Zhou, X Gu, J Xu, Z Liu, Y Zhang, H Li, L Shang, K Wang, K Li, X Zhou, X Dong, Z Qu, S Lu, X Hu, S Ruan, S Luo, J Wu, L Peng, F Cheng, L Pan, J Zou, C Jia, J Wang, X Liu, S Wang, X Wu, Q Ge, J He, H Zhan, F Qiu, L Guo, C Huang, T Jaki, FG Hayden, PW Horby, D Zhang, C Wang. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med 2020 Mar 18. [Epub ahead of print] doi: 10.1056/NEJMoa2001282
https://doi.org/10.1056/NEJMoa2001282
pmid: 32187464
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|